Genprex Taps Andelyn Biosciences for AAV Diabetes Gene Therapy Scale-Up
- Genprex selected Andelyn Biosciences to support manufacturing scale-up for a dual-indication (type 1 and type 2) diabetes gene therapy using AAV vector delivery to the pancreas.
- Andelyn will provide process optimization, IND-enabling studies, cGMP clinical-stage manufacturing, and analytical/potency assay development via its Curator cell and gene therapy platform.
Operational Impact
Andelyn's engagement to deliver IND-enabling and cGMP manufacturing for an AAV gene therapy expands its cell and gene therapy workload and demonstrates capability in complex pancreatic-directed therapies ahead of clinical advancement.
Source: Contract Pharma Breaking News RSS
Lifecore Biomedical Wins Commercial Injectable Transfer; Seventh Late-Stage Program in 2026
- Lifecore signed a technical transfer agreement for a commercially marketed injectable drug with unique formulation and manufacturing complexity.
- The program marks Lifecore's seventh late-stage commercial addition and 11th pipeline program in 2026, with commercial revenues expected in 2028.
- Lifecore's late-stage pipeline now contains 13 programs projected to generate commercial revenues by end of 2028.
Operational Impact
Lifecore's seventh late-stage commercial program adds injectable manufacturing capacity and revenue visibility through 2028, demonstrating successful execution of its commercial pipeline-building strategy and expanding customer relationships in complex injectables.
Source: PharmaSource RSS